Hyperglycemia: Clinical Trials

14 trials for Hyperglycemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 unknown. 14 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 214Unknown 14
Phase 13Unknown 3

Follow Hyperglycemia: new trials by email Literature Review of Hyperglycemia trials Research Report on Hyperglycemia

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Whole Grain Job's Tear, Muscle Health, Blood Glucose and Lipid Level
Taiwanese whole grain job's tear (red job's tear), White job's tear - Sarcopenia, Frailty
Phase 2UnknownTaipei Veterans General Hospital, Taiwan802024-06-142024-07-16
Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients
Dapagliflozin 10mg Tab, lifestyle interventions - Prediabetic State, Impaired Fasting Glucose
Phase 2UnknownYangjin1202023-12-202023-07-25
Early Versus Conventional Cessation of Hydrocortisone in Septic Shock
normal saline solution, Hydrocortisone and normal saline solution - Septic Shock, Adverse Event
Phase 2UnknownMahidol University1602023-07-052024-04-05
Dorzagliatin and 1st Phase Insulin and Beta-cell Glucose Sensitivity in IGT and NGT
Dorzagliatin, Placebo - Glucose Intolerance
Phase 1 / Phase 2UnknownChinese University of Hong Kong202022-08-012022-07-25
Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose
Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg - Impaired Glucose Tolerance, Insulin Sensitivity
Phase 2UnknownOslo University Hospital642021-02-102021-04-08
Magnesium Replacement and Hyperglycemia After Kidney Transplantation
Mablet 360 mg, Placebo - Hypomagnesemia, Kidney Transplantation
Phase 1 / Phase 2UnknownOslo University Hospital402020-02-252021-09-28
Effect of Melatonin and Metformin on Glycemic Control Genotoxicity and Cytotoxicity Markers in Patients With Prediabetes
melatonin, metformin, Placebo - PreDiabetes
Phase 2UnknownUniversity of Guadalajara422019-08-222019-09-26
ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)
ARA 290 - Diabetes Type 2, Impaired Glucose Tolerance
Phase 2UnknownClaes-Göran Östenson242013-10-012015-09-03
Safety, Tolerability, PK, and PD of LIM-0705 in Subjects With Impaired Glucose Tolerance or Abnormal HOMA-IR
LIM-0705, Placebo capsules - Impaired Glucose Tolerance, Insulin Resistance
Phase 2UnknownLimerick BioPharma502011-05-012011-06-02
Genetic Counseling and Lifestyle Change for Diabetes Prevention
Diabetes Genetic Counseling, No genetic counseling - Pre-diabetes, Overweight
Phase 2UnknownMassachusetts General Hospital902009-12-012011-07-20
Effect of Sitagliptin in Impaired Glucose Tolerance
Sitagliptin, Placebo - Impaired Glucose Tolerance
Phase 2UnknownNational Taiwan University Hospital602009-12-012010-03-22
Safety and Efficacy of Autologous Adipose-Derived Stem Cell Transplantation in Type 2 Diabetics
Autologous Adipose-derived Stem cells - Type 2 Diabetes Mellitus
Phase 1 / Phase 2UnknownAdistem Ltd342007-11-012008-07-01
Improving Blood Glucose Control With a Computerized Decision Support Tool: Phase 2
glucose control with computer generated recommendations - Critically Ill, Hyperglycemia
Phase 2UnknownIntermountain Health Care, Inc.2002007-09-012015-02-26
Improving Blood Glucose Control With a Computerized Decision Support Tool: Phase 1
glucose control with computer generated recommendations - Critically Ill, Hyperglycemia
Phase 2UnknownIntermountain Health Care, Inc.2002006-02-012015-02-26

Narrower conditions

Glucose Intolerance (8)  ·  Insulin Resistance (5)  ·  Diabetes Mellitus, Type 2 (3)  ·  Critical Illness (2)  ·  Diabetes Mellitus (2)  ·  Prediabetic State (2)  ·  Frailty (1)  ·  Glucose Metabolism Disorders (1)  ·  Hyperlipidemias (1)  ·  Hypernatremia (1)  ·  Inflammation (1)  ·  Metabolic Syndrome (1)  ·  Muscle Weakness (1)  ·  Overweight (1)

Broader conditions

Metabolic Diseases (14)  ·  Nutritional and Metabolic Diseases (14)  ·  Glucose Metabolism Disorders (13)  ·  Hyperinsulinism (6)  ·  Pathological Conditions, Signs and Symptoms (6)  ·  Endocrine System Diseases (5)  ·  Pathologic Processes (5)  ·  Diabetes Mellitus (3)  ·  Signs and Symptoms (3)  ·  Disease Attributes (2)  ·  Nervous System Diseases (2)  ·  Neurologic Manifestations (2)  ·  Neuromuscular Manifestations (2)  ·  Atrophy (1)

Interventions

Metformin (2)  ·  Biguanides (1)  ·  Dorzagliatin (1)  ·  Hydrocortisone (1)  ·  Melatonin (1)  ·  Saline Solution (1)  ·  Sitagliptin Phosphate (1)  ·  Thiazolidinediones (1)  ·  dapagliflozin (1)

Sponsors

Intermountain Health Care, Inc. (2)  ·  Oslo University Hospital (2)  ·  Adistem Ltd (1)  ·  Chinese University of Hong Kong (1)  ·  Claes-Göran Östenson (1)  ·  Limerick BioPharma (1)  ·  Mahidol University (1)  ·  Massachusetts General Hospital (1)  ·  National Taiwan University Hospital (1)  ·  Taipei Veterans General Hospital, Taiwan (1)  ·  University of Guadalajara (1)  ·  Yangjin (1)

Countries

United States (4)  ·  Norway (2)  ·  Taiwan (2)  ·  China (1)  ·  Mexico (1)  ·  Philippines (1)  ·  Sweden (1)  ·  Thailand (1)

Top investigators

Alan H Morris, MD (2)  ·  Anchun Hwang, Doctor (1)  ·  Bill Paspaliaris, PhD (1)  ·  Emeritta A Barrenechea, MD (1)  ·  Florencio Q Lucero, MD (1)  ·  Jin Yang, doctorate (1)  ·  Lee-Ming Chuang, MD, PhD (1)  ·  Letitia Lucero-Palma, MD (1)  ·  Linda Morrow, MD (1)  ·  Lizet Yadira Rosales-Rivera, PhD Science (1)  ·  Richard W Grant, MD MPH (1)  ·  Surat Tongyoo, Doctor (1)

Results publications

PMID 22302620, PMID 22933432, PMID 38494571

NIH funding

R21DK084527 (1)